Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP + Tislelizumab + Ociperlimab in Advanced BTC
NCT05019677Phase 2Withdrawn
- Sponsor
- Fudan University
- Start
- Sep 2021
- Primary completion
- Dec 2024
- Modality
- IgG Antibodies, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, ociperlimab in biliary tract carcinoma (BTC), sponsored by Fudan University. Planned start Sep 2021; status: withdrawn.
02
Drugs
tislelizumabociperlimab
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT05019677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05019677.